All articles tagged with #enzyme inhibition
Researchers have developed a promising new compound, CMX410, that targets a vital enzyme in tuberculosis bacteria, showing effectiveness against drug-resistant strains and offering hope for improved treatments for the deadliest infectious disease.
Stanford scientists discovered that inhibiting the overactive enzyme LRRK2 in mice can restore neuron communication and potentially slow Parkinson's progression, offering hope for early intervention and treatment across different Parkinson's types.
Scientists discovered that inhibiting the overactive enzyme LRRK2 in mice with a Parkinson's-related mutation can restore damaged brain cells, regrow cellular antennae called cilia, and improve dopamine signaling, suggesting a potential approach to reverse early Parkinson’s damage.
A study from the University of Mississippi and Georgetown University found that a sugar compound derived from sea cucumbers can inhibit an enzyme linked to cancer growth, potentially offering a safer and effective treatment option without the side effects of current therapies.
Inhibiting the enzyme USP30 in a mouse model has been found to protect dopamine-producing neurons, which are typically lost as Parkinson's disease progresses. This groundbreaking discovery offers a new therapeutic approach that could potentially slow or even prevent the progression of Parkinson's. The study utilized genetic knockout models and a proprietary molecule to block USP30, resulting in increased clearance of damaged mitochondria. These findings provide hope for the development of treatments that could modify the course of Parkinson's disease.
Researchers at Beth Israel Deaconess Medical Center have made significant progress in understanding the progression of Parkinson's disease (PD) by inhibiting a specific enzyme in a mouse model. By targeting the enzyme USP30, which plays a role in the clearance of dysfunctional mitochondria in dopamine-producing neurons, the researchers were able to protect against the loss of these neurons and halt the development of PD-like motor symptoms. These findings offer potential for the development of therapeutics that could slow or prevent the progression of Parkinson's disease in humans.